{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:41:17Z","timestamp":1768876877848,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.clinthera.2012.04.024","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T15:08:43Z","timestamp":1337785723000},"page":"1259-1272.e1","source":"Crossref","is-referenced-by-count":21,"title":["Loteprednol Etabonate Suspension 0.2% Administered QID Compared With Olopatadine Solution 0.1% Administered BID in the Treatment of Seasonal Allergic Conjunctivitis: A Multicenter, Randomized, Investigator-Masked, Parallel Group Study in Chinese Patients"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct01435460","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lan","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghuai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linnong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangshun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Elion-Mboussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lipika","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.04.024_bib1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1365-2222.2001.01148.x","article-title":"Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies","volume":"31","author":"Anderson","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.clinthera.2012.04.024_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2010.06.050","article-title":"The epidemiology of ocular and nasal allergy in the United States, 1988\u20131994","volume":"126","author":"Singh","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib3","first-page":"35","article-title":"Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders","volume":"9","author":"Bielory","year":"2007","journal-title":"MedGenMed"},{"key":"10.1016\/j.clinthera.2012.04.024_bib4","article-title":"Management of seasonal allergic conjunctivitis: guide to therapy","author":"Bielory","year":"2011","journal-title":"Acta Ophtahlmol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00130832-200410000-00016","article-title":"Developments in ocular allergy","volume":"4","author":"Chambless","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib6","first-page":"485","article-title":"Ocular allergy: diagnosis and treatment","volume":"18","author":"Butrus","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.clinthera.2012.04.024_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14728214.10.3.505","article-title":"Emerging drugs for ocular allergy","volume":"10","author":"Leonardi","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.clinthera.2012.04.024_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.ICL.0000092071.82938.46","article-title":"Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis","volume":"30","author":"Ilyas","year":"2004","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.clinthera.2012.04.024_bib9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/00016480410022525","article-title":"Effect of glucocorticoid on upregulation of histamine H1 receptor mRNA in nasal mucosa of rats sensitized by exposure to toluene diisocyanate","volume":"124","author":"Kitamura","year":"2004","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1254\/jphs.FM0070184","article-title":"Progress in allergy signal research on mast cells: up-regulation of histamine signal-related gene expression in allergy model rats","volume":"106","author":"Fukui","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2012.04.024_bib11","first-page":"809","article-title":"Properties of olopatadine hydrochloride, a new antiallergic\/antihistaminic drug","volume":"54","author":"Ohmori","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2012.04.024_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archopht.117.5.643","article-title":"Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs","volume":"117","author":"Yanni","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1081-1206(10)63063-3","article-title":"Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells","volume":"79","author":"Yanni","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/02713689109020329","article-title":"Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes","volume":"10","author":"Druzgala","year":"1991","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.clinthera.2012.04.024_bib15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00061198-199808000-00009","article-title":"Change in intraocular pressure during long-term use of loteprednol etabonate","volume":"7","author":"Novack","year":"1998","journal-title":"J Glaucoma"},{"key":"10.1016\/j.clinthera.2012.04.024_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.1993.9.157","article-title":"Intraocular pressure response to loteprednol etabonate in known steroid responders","volume":"9","author":"Bartlett","year":"1993","journal-title":"J Ocul Pharmacol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib17","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1172\/JCI111599","article-title":"Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts","volume":"74","author":"Manabe","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2012.04.024_bib18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0149-2918(03)80115-7","article-title":"A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis","volume":"25","author":"Abelson","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.04.024_bib19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0149-2918(02)80060-1","article-title":"A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis","volume":"24","author":"Katelaris","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.04.024_bib20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0161-6420(99)90077-5","article-title":"A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis","volume":"106","author":"Shulman","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2012.04.024_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0091-6749(98)70094-6","article-title":"A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis","volume":"102","author":"Dell","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/OPTH.S3294","article-title":"Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops","volume":"2","author":"Uchio","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib26","series-title":"Multiple Testing Problem in Pharmaceutical Statistics","first-page":"138","article-title":"Analysis of multiple endpoints in clinical trials","author":"Dmitrienko","year":"2010"},{"key":"10.1016\/j.clinthera.2012.04.024_bib27","series-title":"SAS for Mixed Models","first-page":"159","article-title":"Analysis of repeated measures data","author":"Littell","year":"2008"},{"key":"10.1016\/j.clinthera.2012.04.024_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.1998.34.3.485181","article-title":"Seasonal allergic conjunctivitis","volume":"34","author":"Joss","year":"1998","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.clinthera.2012.04.024_bib29","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0886-3350(98)80170-3","article-title":"Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation","volume":"24","author":"Stewart","year":"1998","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.clinthera.2012.04.024_bib30","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0161-6420(98)99054-6","article-title":"A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation","volume":"105","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2012.04.024_bib31","first-page":"177","article-title":"Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery","volume":"5","author":"Comstock","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0002-9394(14)70171-0","article-title":"A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis","volume":"123","author":"Friedlaender","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib33","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","article-title":"A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis","volume":"123","author":"Dell","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2012.04.024_bib34","unstructured":"Koo EH, Samudre S, Williams PB. Loteprednol etabonate ophthalmic suspension 0.2% (ALREX\u00ae) and olopatadine hydrochloride ophthalmic solution 0.1% (PATANOL\u00ae) in the treatment of allergic conjunctivitis. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, April 27\u2013May 1, 2008, Fort Lauderdale, FL."},{"key":"10.1016\/j.clinthera.2012.04.024_bib35","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0149-2918(02)80007-8","article-title":"Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model","volume":"24","author":"Berdy","year":"2002","journal-title":"Clin Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T07:55:52Z","timestamp":1542959752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812002883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0149291812002883"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.04.024","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}